Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

NCT00142181 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Lymphoplasmacytic Lymphoma
Waldenstrom's Macroglobulinemia

Interventions

DRUG: Campath-1H

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]